Moderna (MRNA)
(Delayed Data from NSDQ)
$63.93 USD
+0.29 (0.46%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $63.81 -0.12 (-0.19%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.93 USD
+0.29 (0.46%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $63.81 -0.12 (-0.19%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Zacks News
Company News for Feb 27, 2023
by Zacks Equity Research
Companies in The News Are: NVDA, BA, ADBE, MRNA
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
by Kinjel Shah
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y
by Zacks Equity Research
Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $171.48, moving +1.3% from the previous trading session.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSP
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session.
Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RSP
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $174.30, marking a -1% move from the previous day.
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag
by Zacks Equity Research
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy
by Zacks Equity Research
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Stock Moves 1.89%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $193.98, marking a +1.89% move from the previous day.
Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds
by Kinjel Shah
FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.